BP PLC ADR (BP)vsGlaxoSmithKline PLC ADR (GSK)
BP
BP PLC ADR
$43.34
-1.07%
ENERGY · Cap: $114.92B
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
Smart Verdict
WallStSmart Research — data-driven comparison
BP PLC ADR generates 489% more annual revenue ($193.00B vs $32.78B). GSK leads profitability with a 17.8% profit margin vs 1.7%. BP appears more attractively valued with a PEG of 0.05. GSK earns a higher WallStSmart Score of 66/100 (B-).
BP
Strong Buy65
out of 100
Grade: B-
GSK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+26.9%
Fair Value
$52.77
Current Price
$43.34
$9.43 discount
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Earnings expanding 474.5% YoY
Large-cap with strong market position
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.4x book value
ROE of 5.8% — below average capital efficiency
1.7% margin — thin
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BP
The strongest argument for BP centers on PEG Ratio, EPS Growth, Market Cap. Revenue growth of 11.6% demonstrates continued momentum. PEG of 0.05 suggests the stock is reasonably priced for its growth.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : BP
The primary concerns for BP are P/E Ratio, Price/Book, Return on Equity. Thin 1.7% margins leave little buffer for downturns.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
GSK carries more volatility with a beta of 0.30 — expect wider price swings.
BP is growing revenue faster at 11.6% — sustainability is the question.
GSK generates stronger free cash flow (698M), providing more financial flexibility.
Monitor OIL & GAS INTEGRATED industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GSK scores higher overall (66/100 vs 65/100), backed by strong 17.8% margins. BP offers better value entry with a 26.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BP PLC ADR
ENERGY · OIL & GAS INTEGRATED · USA
BP plc participates in the energy business globally. The company is headquartered in London, the United Kingdom.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other OIL & GAS INTEGRATED Stocks
Want to dig deeper into these stocks?